CEL-SCI CORPORATION Stock or Unit Option Plan Expense
CEL-SCI CORPORATION (CVM) reported Stock or Unit Option Plan Expense of $234.33 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:StockOptionPlanExpense · last filed 2024-05-15
- CEL-SCI CORPORATION stock or unit option plan expense for the quarter ending 2024-03-31 was $234.33K.
- CEL-SCI CORPORATION stock or unit option plan expense for the quarter ending 2013-12-31 was $510.28K, a 47.21% decline year-over-year.
- CEL-SCI CORPORATION stock or unit option plan expense for the quarter ending 2013-09-30 was $549.19K, a 8.76% increase year-over-year.
- CEL-SCI CORPORATION stock or unit option plan expense for the quarter ending 2013-06-30 was $564.37K, a 21.81% increase year-over-year.
- CEL-SCI CORPORATION stock or unit option plan expense for fiscal 2013 was $2.64M, a 18.28% increase from fiscal 2012.
- CEL-SCI CORPORATION stock or unit option plan expense for fiscal 2012 was $2.23M, a 45.20% increase from fiscal 2011.
- CEL-SCI CORPORATION stock or unit option plan expense for fiscal 2011 was $1.54M, a 16.63% increase from fiscal 2010.
- CEL-SCI CORPORATION stock or unit option plan expense for fiscal 2010 was $1.32M, a 22.54% decline from fiscal 2009.
| Period end | Stock or Unit Option Plan Expense 3 month | Stock or Unit Option Plan Expense 6 month | Stock or Unit Option Plan Expense 9 month | Stock or Unit Option Plan Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $234.33K 10-Q · filed 2024-05-15 | |||
| 2013-12-31 | $510.28K 10-Q · filed 2014-02-10 | $1.06M derived: sum of 2 quarters · filed 2014-02-10 | $1.62M derived: sum of 3 quarters · filed 2014-02-10 | $2.18M derived: sum of 4 quarters · filed 2014-02-10 |
| 2013-09-30 | $549.19K derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-27 | $1.11M derived: sum of 2 quarters · filed 2013-12-27 | $1.67M derived: sum of 3 quarters · filed 2013-12-27 | $2.64M 10-K · filed 2013-12-27 |
| 2013-06-30 | $564.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-09 | $1.12M derived: sum of 2 quarters · filed 2013-08-09 | $2.09M 10-Q · filed 2013-08-09 | $2.59M derived: sum of 4 quarters · filed 2014-02-10 |
| 2013-03-31 | $556.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-05-10 | $1.52M 10-Q · filed 2013-05-10 | $2.03M derived: sum of 3 quarters · filed 2014-02-10 | $2.49M derived: sum of 4 quarters · filed 2014-02-10 |
| 2012-12-31 | $966.59K 10-Q · filed 2014-02-10 | $1.47M derived: sum of 2 quarters · filed 2014-02-10 | $1.93M derived: sum of 3 quarters · filed 2014-02-10 | $2.36M derived: sum of 4 quarters · filed 2014-02-10 |
| 2012-09-30 | $504.95K derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-27 | $968.27K derived: sum of 2 quarters · filed 2013-12-27 | $1.39M derived: sum of 3 quarters · filed 2013-12-27 | $2.23M 10-K · filed 2013-12-27 |
| 2012-06-30 | $463.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-09 | $886.92K derived: sum of 2 quarters · filed 2013-08-09 | $1.72M 10-Q · filed 2013-08-09 | $2.15M derived: sum of 4 quarters · filed 2013-12-27 |
| 2012-03-31 | $423.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-05-10 | $1.26M 10-Q · filed 2013-05-10 | $1.69M derived: sum of 3 quarters · filed 2013-12-27 | $2.10M derived: sum of 4 quarters · filed 2013-12-27 |
| 2011-12-31 | $837.46K 10-Q · filed 2013-02-08 | $1.27M derived: sum of 2 quarters · filed 2013-12-27 | $1.68M derived: sum of 3 quarters · filed 2013-12-27 | $2.01M derived: sum of 4 quarters · filed 2013-12-27 |
| 2011-09-30 | $430.40K derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-27 | $837.87K derived: sum of 2 quarters · filed 2013-12-27 | $1.17M derived: sum of 3 quarters · filed 2013-12-27 | $1.54M 10-K · filed 2013-12-27 |
| 2011-06-30 | $407.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-08-09 | $742.86K derived: sum of 2 quarters · filed 2012-08-09 | $1.10M 10-Q · filed 2012-08-09 | $1.48M derived: sum of 4 quarters · filed 2012-12-14 |
| 2011-03-31 | $335.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-05-10 | $697.46K 10-Q · filed 2012-05-10 | $1.07M derived: sum of 3 quarters · filed 2012-12-14 | |
| 2010-12-31 | $362.08K 10-Q · filed 2012-02-09 | $739.13K derived: sum of 2 quarters · filed 2012-12-14 | ||
| 2010-09-30 | $377.05K derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-14 | $1.32M 10-K · filed 2012-12-14 | ||
| 2010-06-30 | $939.35K 10-Q · filed 2011-08-09 | |||
| 2009-09-30 | $1.70M 10-K · filed 2011-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |